Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | AOC1 | P19801 | 2/20 | 0.48 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cis-Urocanic Acid SCHEMBL1136889 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| Cis-Urocanic Acid SCHEMBL12963908 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL15668642 | 0.82 | CYP3A4 (0.70) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL23749602 | 0.82 | CYP3A4 (0.70) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL8086657 | 0.79 | — | — | |
| SCHEMBL8552929 | 0.78 | KMT2A (1.00) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL21334959 | 0.78 | KMT2A (1.00) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL25101013 | 0.78 | KDM4E (0.64) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL2567149 | 0.74 | MEN1 (0.69) | CYP3A4TSHRKDM4EBLMNPSR1 | |
| SCHEMBL11598554 | 0.74 | MEN1 (0.69) | CYP3A4TSHRKDM4EBLMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-3976811-B1 | METABOLOMIC CHARACTERIZATION OF MICROORGANISMS | LEWIS IAN ANDREW (CA) | 2026-02-11 | — | — | EP | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| EP-4452259-A1 | COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Société des Produits Nestlé S.A. (CH) | 2024-10-30 | — | — | EP | claimed |
| EP-4440342-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118714936-A | Methods and uses of microbial compositions, components or metabolites for the treatment of vagal nerve related diseases, disorders and conditions | 奇迹生物公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118425363-A | Method for simultaneously measuring trans-urocanic acid, cis-urocanic acid, histidine and histamine in fish products | 江苏科技大学 | 2024-08-02 | — | — | CN | claimed |
| WO-2023102149-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2023-06-08 | — | — | WO | claimed |
| CN-116003710-A | Polyacrylic polymer modified substrate, preparation method thereof and application thereof in preparation of biochip | 中国海洋大学 | 2023-04-25 | — | — | CN | claimed |
| WO-2023044076-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. (US) | 2023-03-23 | — | — | WO | claimed |
| US-20230087305-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. | 2023-03-23 | — | — | US | claimed |
| WO-2022192755-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220082554-A1 | Prediction and/or Determination Marker for Effectiveness of Treatment with Drug Containing PD-1 Signal Inhibitor | KYOTO UNIVERSITY (JP) | 2022-03-17 | — | — | US | claimed |
| EP-1060223-B1 | PHOTOCHROMIC COATING COMPOUND AND SUBSTRATE COATED WITH SAME | INST NEUE MAT GEMEIN GMBH (DE) | 2004-08-18 | — | — | EP | claimed |
| US-6639039-B1 | Polysiloxane precondensate having curable glycidol or methacryl functionality, dye, stabilizer and particles; light and scratch resistance | Institut für Neue Materialien Gemeinnützige GmbH (DE) | 2003-10-28 | — | — | US | claimed |
| EP-1060223-A1 | PHOTOCHROMIC COATING COMPOUND AND SUBSTRATE COATED WITH SAME | Institut Für Neue Materialien gem. GmbH (DE) | 2000-12-20 | — | — | EP | claimed |
| WO-1999041326-A1 | PHOTOCHROMIC COATING COMPOUND AND SUBSTRATE COATED WITH SAME | INSTITUT FÜR NEUE MATERIALIEN GEM. GMBH (DE) | 1999-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | CYP3A4 1976/4885TSHR 1923/4885KDM4E 4749/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | CYP3A4 4804/4885TSHR 2407/4885KDM4E 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.